Trial Profile

Phase I Study of Everolimus (RAD001) in Combination With Lenalidomide in Patients With Advanced Solid Malignancies Enriched for Renal Cell Carcinoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 31 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Lenalidomide (Primary)
Indications Adenocarcinoma; Neuroendocrine tumours; Renal cell carcinoma; Solid tumours
Focus Adverse reactions

Most Recent Events

15 Mar 2018 Status changed from active, no longer recruiting to completed.
01 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
01 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com